Diabetes drug metformin tested to prevent lung cancer in overweight former smokers
NCT ID NCT04931017
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether metformin, a safe and widely used diabetes drug, can lower the risk of lung cancer in overweight or obese former smokers who are at high risk. About 50 participants will take metformin for 6 months to see if it reduces certain immune cells linked to tumor growth. The goal is to find a simple, low-cost way to prevent lung cancer in this vulnerable group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BC Cancer Research Centre
Vancouver, British Columbia, V5Z 1L3, Canada
-
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, 80045, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of British Columbia Hospital
Vancouver, British Columbia, V6T 2B5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could spot cancers that standard scans overlook
- Can a conversation aid empower lung cancer patients?
- Can couples coping together ease the burden of advanced cancer?
- Can a custom toolkit help indigenous smokers spot lung cancer earlier?
- Study tests if teaching doctors and patients boosts lung cancer screening
- Could a vaccine stop lung cancer in smokers? early trial launches